170 related articles for article (PubMed ID: 17112739)
1. Motexafin gadolinium: a novel redox active drug for cancer therapy.
Magda D; Miller RA
Semin Cancer Biol; 2006 Dec; 16(6):466-76. PubMed ID: 17112739
[TBL] [Abstract][Full Text] [Related]
2. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.
Magda D; Lecane P; Miller RA; Lepp C; Miles D; Mesfin M; Biaglow JE; Ho VV; Chawannakul D; Nagpal S; Karaman MW; Hacia JG
Cancer Res; 2005 May; 65(9):3837-45. PubMed ID: 15867382
[TBL] [Abstract][Full Text] [Related]
3. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
Mehta MP; Rodrigus P; Terhaard CH; Rao A; Suh J; Roa W; Souhami L; Bezjak A; Leibenhaut M; Komaki R; Schultz C; Timmerman R; Curran W; Smith J; Phan SC; Miller RA; Renschler MF
J Clin Oncol; 2003 Jul; 21(13):2529-36. PubMed ID: 12829672
[TBL] [Abstract][Full Text] [Related]
4. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.
Mehta MP; Shapiro WR; Phan SC; Gervais R; Carrie C; Chabot P; Patchell RA; Glantz MJ; Recht L; Langer C; Sur RK; Roa WH; Mahe MA; Fortin A; Nieder C; Meyers CA; Smith JA; Miller RA; Renschler MF
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1069-76. PubMed ID: 18977094
[TBL] [Abstract][Full Text] [Related]
5. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin.
Miller RA; Woodburn KW; Fan Q; Lee I; Miles D; Duran G; Sikic B; Magda D
Clin Cancer Res; 2001 Oct; 7(10):3215-21. PubMed ID: 11595717
[TBL] [Abstract][Full Text] [Related]
6. Motexafin gadolinium induces mitochondrially-mediated caspase-dependent apoptosis.
Chen J; Ramos J; Sirisawad M; Miller R; Naumovski L
Apoptosis; 2005 Oct; 10(5):1131-42. PubMed ID: 16151646
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd).
Zahedi Avval F; Berndt C; Pramanik A; Holmgren A
Biochem Biophys Res Commun; 2009 Feb; 379(3):775-9. PubMed ID: 19121624
[TBL] [Abstract][Full Text] [Related]
8. Effects of motexafin gadolinium on DNA damage and X-ray-induced DNA damage repair, as assessed by the Comet assay.
Donnelly ET; Liu Y; Paul TK; Rockwell S
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1176-86. PubMed ID: 15990023
[TBL] [Abstract][Full Text] [Related]
9. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase.
Hashemy SI; Ungerstedt JS; Zahedi Avval F; Holmgren A
J Biol Chem; 2006 Apr; 281(16):10691-7. PubMed ID: 16481328
[TBL] [Abstract][Full Text] [Related]
10. Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines.
Lecane PS; Karaman MW; Sirisawad M; Naumovski L; Miller RA; Hacia JG; Magda D
Cancer Res; 2005 Dec; 65(24):11676-88. PubMed ID: 16357179
[TBL] [Abstract][Full Text] [Related]
11. Ascorbate and endocytosed Motexafin gadolinium induce lysosomal rupture.
Berndt C; Kurz T; Bannenberg S; Jacob R; Holmgren A; Brunk UT
Cancer Lett; 2011 Aug; 307(2):119-23. PubMed ID: 21492999
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive and nondestructive optical spectroscopic measurement of motexafin gadolinium in mouse tissues: comparison to high-performance liquid chromatography.
Kanick SC; Eiseman JL; Joseph E; Guo J; Parker RS
J Photochem Photobiol B; 2007 Sep; 88(2-3):90-104. PubMed ID: 17604637
[TBL] [Abstract][Full Text] [Related]
13. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy.
Biaglow JE; Miller RA
Cancer Biol Ther; 2005 Jan; 4(1):6-13. PubMed ID: 15684606
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of reactive oxygen species in cancer therapy.
Renschler MF
Eur J Cancer; 2004 Sep; 40(13):1934-40. PubMed ID: 15315800
[TBL] [Abstract][Full Text] [Related]
15. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
Khuntia D; Mehta M
Expert Rev Anticancer Ther; 2004 Dec; 4(6):981-9. PubMed ID: 15606327
[TBL] [Abstract][Full Text] [Related]
16. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Forouzannia A; Richards GM; Khuntia D; Mehta MP
Expert Rev Anticancer Ther; 2007 Jun; 7(6):785-94. PubMed ID: 17555388
[TBL] [Abstract][Full Text] [Related]
17. Gadolinium texaphyrin-methotrexate conjugates. Towards improved cancer chemotherapeutic agents.
Wei WH; Fountain M; Magda D; Wang Z; Lecane P; Mesfin M; Miles D; Sessler JL
Org Biomol Chem; 2005 Sep; 3(18):3290-6. PubMed ID: 16132091
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI.
Hirschberg H; Wu GN; Madsen SJ
Minim Invasive Neurosurg; 2007 Dec; 50(6):318-23. PubMed ID: 18210352
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic strategies by modulating oxygen stress in cancer and inflammation.
Fang J; Seki T; Maeda H
Adv Drug Deliv Rev; 2009 Apr; 61(4):290-302. PubMed ID: 19249331
[TBL] [Abstract][Full Text] [Related]
20. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
Tonissen KF; Di Trapani G
Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
